Definium Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
DFTX$34.64-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2026 | 2025 |
| Operating expenses: | ||
| Research and development | $41,484 | $23,357 |
| General and administrative | 17,736 | 8,802 |
| Total operating expenses | 59,220 | 32,159 |
| Loss from operations | (59,220) | (32,159) |
| Other income/(expense): | ||
| Interest income | 3,457 | 2,433 |
| Interest expense | (1,245) | (602) |
| Foreign exchange loss, net | (44) | (19) |
| Change in fair value of 2022 USD Financing Warrants | (20,046) | 6,999 |
| Total other income/(expense) | (17,878) | 8,811 |
| Net loss | (77,098) | (23,348) |
| Other comprehensive loss | ||
| Unrealized gain/(loss) on investments | (262) | 10 |
| Gain/(loss) on foreign currency translation | 1 | (27) |
| Comprehensive loss | $(77,359) | $(23,365) |
| Net loss per common share, basic | $(0.71) | $(0.27) |
| Net loss per common share, diluted | $(0.71) | $(0.35) |
| Weighted-average common shares, basic | 108,790,941 | 85,067,855 |
| Weighted-average common shares, diluted | 108,790,941 | 87,091,461 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.